Contributors |
|
xi | |
Foreword |
|
xiii | |
Preface |
|
xv | |
Acknowledgments |
|
xvii | |
|
|
1 | (16) |
|
|
|
1 | (4) |
|
|
5 | (1) |
|
Glassware and Plasticware |
|
|
6 | (1) |
|
|
7 | (1) |
|
Chemical Reagents and Handling |
|
|
8 | (1) |
|
Reference Materials and Controls |
|
|
9 | (1) |
|
|
10 | (1) |
|
Basic Chemistry Equipment |
|
|
11 | (2) |
|
|
13 | (2) |
|
|
15 | (2) |
|
Laboratory Reagents and Calculations |
|
|
17 | (10) |
|
|
|
17 | (1) |
|
|
17 | (1) |
|
|
17 | (9) |
|
|
26 | (1) |
|
|
27 | (14) |
|
|
|
27 | (1) |
|
|
27 | (2) |
|
|
29 | (1) |
|
|
30 | (5) |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
|
37 | (1) |
|
Laboratory Safety Program |
|
|
38 | (1) |
|
|
38 | (1) |
|
Resources for Safety Information |
|
|
39 | (2) |
|
|
41 | (24) |
|
|
The Quality Management Framework |
|
|
41 | (1) |
|
Quality Control Monitoring |
|
|
42 | (20) |
|
|
62 | (3) |
|
Method Evaluation and Preanalytical Variables |
|
|
65 | (16) |
|
|
|
65 | (8) |
|
|
73 | (1) |
|
|
74 | (3) |
|
Components of an Effective CQI/QA Program |
|
|
77 | (1) |
|
|
78 | (3) |
|
|
81 | (14) |
|
|
Spectrophotometric Principles |
|
|
81 | (4) |
|
Sepctrohotometric Instruments |
|
|
85 | (8) |
|
|
93 | (2) |
|
Principles of Molecular and Immunoassays |
|
|
95 | (36) |
|
|
|
95 | (3) |
|
Specimen Collection and Handling |
|
|
98 | (1) |
|
|
98 | (6) |
|
|
104 | (4) |
|
|
108 | (2) |
|
|
110 | (18) |
|
|
128 | (3) |
|
|
131 | (10) |
|
|
|
131 | (1) |
|
Stages of Automated Analysis |
|
|
132 | (4) |
|
Examples of Specific Systems |
|
|
136 | (2) |
|
|
138 | (1) |
|
|
138 | (3) |
|
Computers in the Clinical Laboratory |
|
|
141 | (12) |
|
|
Computer Hardware and Software |
|
|
141 | (6) |
|
Networking and Communication |
|
|
147 | (4) |
|
Laboratory Information Systems |
|
|
151 | (1) |
|
|
151 | (1) |
|
|
152 | (1) |
|
|
153 | (26) |
|
|
Definitions and Basic Principles |
|
|
153 | (1) |
|
|
153 | (3) |
|
|
156 | (1) |
|
|
157 | (2) |
|
|
159 | (10) |
|
Cerebrospinal Fluid Glucose |
|
|
169 | (1) |
|
|
169 | (6) |
|
|
175 | (4) |
|
|
179 | (24) |
|
|
|
179 | (3) |
|
|
182 | (2) |
|
|
184 | (4) |
|
Analytical Procedures for Lipids |
|
|
188 | (4) |
|
|
192 | (6) |
|
|
198 | (5) |
|
|
203 | (20) |
|
|
|
203 | (3) |
|
Metabolism: Synthesis and Degradation |
|
|
206 | (1) |
|
General Analytical Processes |
|
|
206 | (5) |
|
|
211 | (9) |
|
Protein in Other Body Fluids |
|
|
220 | (1) |
|
|
221 | (2) |
|
Inherited Metabolic Disorders |
|
|
223 | (16) |
|
|
Overview of Genetic Disorders |
|
|
223 | (5) |
|
Clinical Applications in Detecting Metabolic Related Disorders |
|
|
228 | (8) |
|
Analytical Procedures: Past, Present, and Anticipated |
|
|
236 | (1) |
|
|
237 | (2) |
|
|
239 | (22) |
|
|
|
239 | (5) |
|
|
244 | (11) |
|
|
255 | (6) |
|
|
261 | (24) |
|
|
|
261 | (8) |
|
Clinically Significant Enzymes |
|
|
269 | (9) |
|
|
278 | (5) |
|
|
283 | (2) |
|
|
285 | (38) |
|
|
|
285 | (1) |
|
|
286 | (4) |
|
|
290 | (7) |
|
|
297 | (22) |
|
|
319 | (4) |
|
|
323 | (20) |
|
|
Characteristics of an Ideal Tumor Marker |
|
|
324 | (1) |
|
|
324 | (1) |
|
|
324 | (1) |
|
|
325 | (12) |
|
|
337 | (2) |
|
|
339 | (1) |
|
|
340 | (3) |
|
|
343 | (12) |
|
|
Biosynthesis of Porphyrins and Heme |
|
|
345 | (1) |
|
|
346 | (3) |
|
Laboratory Diagnosis of Porphyrin Disorders |
|
|
349 | (1) |
|
|
350 | (3) |
|
|
353 | (2) |
|
Renal Anatomy and Physiology |
|
|
355 | (18) |
|
|
|
355 | (7) |
|
|
362 | (9) |
|
|
371 | (2) |
|
Renal Function: Nonprotein Nitrogen Compounds, Function Tests, and Renal Disease |
|
|
373 | (28) |
|
|
Nonprotein Nitrogen Compounds |
|
|
373 | (7) |
|
Assessment of Renal Function |
|
|
380 | (11) |
|
|
391 | (6) |
|
|
397 | (4) |
|
|
401 | (20) |
|
|
|
401 | (1) |
|
|
401 | (1) |
|
|
402 | (14) |
|
|
416 | (3) |
|
|
419 | (2) |
|
Acid-Base and Blood Gas Physiology |
|
|
421 | (20) |
|
|
|
421 | (5) |
|
Maintenance of Acid-Base Balance |
|
|
426 | (5) |
|
Disturbances of Acid-Base Balance |
|
|
431 | (4) |
|
|
435 | (3) |
|
|
438 | (3) |
|
Therapeutic Drug Monitoring |
|
|
441 | (14) |
|
|
|
441 | (1) |
|
|
442 | (3) |
|
|
445 | (2) |
|
Variable Affecting Drug Disposition |
|
|
447 | (1) |
|
Sample Collection and Data Reporting |
|
|
447 | (1) |
|
Therapeutic Drug Monitoring |
|
|
448 | (4) |
|
|
452 | (3) |
|
|
455 | (22) |
|
|
Classes of Toxic Substances |
|
|
455 | (11) |
|
Drugs of Abuse and Overdose |
|
|
466 | (5) |
|
|
471 | (3) |
|
|
474 | (3) |
|
Introduction to Hormones and Endocrinology |
|
|
477 | (6) |
|
|
Classification of Hormones |
|
|
477 | (3) |
|
Regulation of Hormone Secretion |
|
|
480 | (1) |
|
|
480 | (1) |
|
Disorders of the Endocrine System |
|
|
481 | (1) |
|
|
481 | (2) |
|
Hypothalamus and Pituitary Endocrinology |
|
|
483 | (8) |
|
|
|
483 | (1) |
|
|
483 | (1) |
|
Pituitary (Hypophysis) Gland |
|
|
483 | (6) |
|
|
489 | (2) |
|
|
491 | (20) |
|
|
|
491 | (1) |
|
|
491 | (5) |
|
|
496 | (5) |
|
|
501 | (7) |
|
|
508 | (3) |
|
The Parathyroid Glands and Calcium-Phosphate Metabolism |
|
|
511 | (10) |
|
|
|
|
511 | (1) |
|
|
511 | (1) |
|
Regulation of Calcium and Phosphorus |
|
|
511 | (2) |
|
|
513 | (2) |
|
|
515 | (4) |
|
|
519 | (2) |
|
Adrenocortical Endocrinology |
|
|
521 | (10) |
|
|
|
521 | (1) |
|
|
521 | (4) |
|
|
525 | (1) |
|
|
526 | (2) |
|
|
528 | (3) |
|
Adrenal Medullary Endocrinology |
|
|
531 | (6) |
|
|
|
531 | (1) |
|
Adrenal Medullary Hormones |
|
|
531 | (3) |
|
|
534 | (1) |
|
|
535 | (2) |
|
Reproductive Endocrinology |
|
|
537 | (20) |
|
|
|
537 | (3) |
|
Female Reproductive System |
|
|
540 | (4) |
|
Structure and Function of Gonadal Steroids |
|
|
544 | (3) |
|
Mechanism of Hormone Action |
|
|
547 | (2) |
|
|
549 | (2) |
|
|
551 | (2) |
|
Defects of Androgen Metabolism |
|
|
553 | (1) |
|
|
554 | (1) |
|
|
554 | (3) |
|
Gastrointestinal and Pancreatic Function |
|
|
557 | (22) |
|
|
|
557 | (3) |
|
|
560 | (1) |
|
|
561 | (1) |
|
Regulation of Digestion by Gastrointestinal Hormones |
|
|
562 | (1) |
|
|
563 | (7) |
|
Laboratory Diagnosis of Dysfunction |
|
|
570 | (7) |
|
|
577 | (2) |
|
Nutritional Status Assessment |
|
|
579 | (34) |
|
|
|
|
579 | (1) |
|
|
580 | (6) |
|
Vitamins and Mineral Status |
|
|
586 | (14) |
|
Trace and Ultratrace Elements |
|
|
600 | (8) |
|
|
608 | (5) |
|
|
613 | (6) |
|
|
|
613 | (1) |
|
|
614 | (2) |
|
POCT Testing and Instrumentation |
|
|
616 | (1) |
|
|
617 | (1) |
|
|
617 | (2) |
|
Laboratory Assessment of Psychiatric Disorders |
|
|
619 | (6) |
|
|
Supporting the Psychiatric Diagnosis and Plan of Treatment |
|
|
619 | (1) |
|
Medical Conditions Underlying Diagnosis and Treatment |
|
|
620 | (1) |
|
Screening for the Biochemical Basis of Psychiatric Disorders |
|
|
621 | (1) |
|
Monitoring Therapeutic Treatment |
|
|
622 | (1) |
|
|
623 | (2) |
|
Biochemical Assessment During Pregnancy |
|
|
625 | (12) |
|
|
|
625 | (4) |
|
|
629 | (4) |
|
|
633 | (2) |
|
|
635 | (2) |
|
Neonatal and Pediatric Laboratory Assessment |
|
|
637 | (12) |
|
Eileen Carreiro-Lawandowski |
|
|
Developmental Differences |
|
|
637 | (1) |
|
|
637 | (3) |
|
Laboratory Assessment in the Pediatric Population |
|
|
640 | (6) |
|
|
646 | (3) |
|
Geriatric Laboratory Assessment |
|
|
649 | (38) |
|
|
|
649 | (2) |
|
|
651 | (3) |
|
|
654 | (16) |
|
|
670 | (1) |
|
|
671 | (5) |
|
|
676 | (1) |
|
|
677 | (4) |
|
|
681 | (6) |
Index |
|
687 | |